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Oral Presentations S21593 days (range 15 - 674) post HSCT. Fourteen (40%) were deter-
mined to have invasive ADV disease (7 on tissue biopsy). ADV viral
load evaluation over time revealed the following: HVL at presenta-
tion in 18 (51.4%) (median 1.1x104,range 7.4x105 - 6.8x109 copies/
ml); 10 (28%) progressed to HVL (median 2 log increase from pre-
sentation) at a median of 15 days (range 3 - 56); and LVL-only at any
time point in 7 (20%) pts (median 4000 copies/ml, range 600 - 8866).
Fifteen pts with HVL were treated with cidovofir intravenously or/
and CMX001 a median 7 doses (range 1 - 38). Despite treatment
with antiviral therapy 12 pts (92%) with HVL and 7 pts (87.5%)
with LVL-HVL died. Mortality was attributable to ADV in 11
(31.4%) pts. All cause 180 day mortality was 74.3% for pts with
ADV.
Conclusions: ADV viremia was relatively low (8.7%) in this high
risk population and similar to the 5% reported in populations receiv-
ing conventional transplants. Determination of viral status in pa-
tients with clinical symptoms resulted in a relatively high yield of
positivity - 40%. Themortality attributable to ADVof 30% suggests
the need for development of better treatment modalities. The 180
day all cause mortality of 74% suggests ADV viremia complicates
other medical conditions and complications of transplant.
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Introduction: Combining haplo-donor stem cells with a full graft
cord blood (CB)-unit has been proposed as a cell support mechanism
which can make single CB available as a donor source for allogeneic
HSCT to a larger proportion of patients: e.g. patients with only do-
nors available with low NC-counts, or with active infections.
Methods: Since 2009 we have a CB+haplo protocol for this group of
patients. Patients (with any indication) with active infection (e.g. fun-
gal) as well as patients with only a CB-unit available below the lower
acceptable cut off were offered a CB+Haplo grafting. All patients re-
ceived myeloablative conditioning (busulfan with therapeutic drug
monitoring in combination with either CY or FLU) and serotherapy
(ATG 8, Campath 1). Haplo-grafts were CD34+ selected (except 1:
CD3/CD19 negative selected). After infusion of the CB, the haplo-
graft containing 5milj/kg CD34+ cells were infused. G-CSF was
given from day +7. GvHD prophylaxis: CsA+pred 1mg/kg.
Results.: 9 patients (8 children, 1 adult; 8 with active infection, 1 low
cell count CBU). Median age was 12.4 yr (range 0.25-41.2 yr). 7 had
a non-malignant disease (5 immunodeficiencies, 1 Osteopetrosis, 1
AA), 2 had a malignant indication. For 2 patients it was their second
transplant. All patients except 1 engrafted at a median time of 12 days
(range 9-15). Thrombocyte engraftment (TBC50) was 36 days
(range14-300). EFS was 33% after a median follow up 249 days
(14-1245). Incidence of GvHD gr. 2-4 was 25%. The non-relapse
mortality was 2/9 (day 14 and day 24 respectively).The initial donor
chimerism at 1 month post SCT showed.80% haplo chimerism in
most patients but all 7 reached a full donor cord blood chimerism
(.95%) within a median period of 121 days (28-925 days) post SCT.
Conclusion: Coinfusion of Haplo with (unrelated) CB transplanta-
tion is a safe and effective option for a group of very high risk patients
(including patients with higher non-engraftment risks) to secure
early engraftment. Haplo-support leads to early haplo-engraftment
switching to full CB donor-chimerism within 4 months, allowing
a normal immune recovery and repertoire.34
CD8-DEPLETED DONOR-LYMPHOCYTE INFUSIONS AFTER T-CELL DE-
PLETED ALLOGENEIC HEMOPOIETIC STEM CELL TRANSPLANTATION
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Meyer, R.G. University Medical Center of the Johannes Gutenberg-Uni-
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In a phase I/II clinical trial, we investigated the prophylactic use of
CD8-depleted (CD8depl) donor lymphocyte infusions (DLI) in thesetting of T-cell depleted allogeneic hematopoietic stem cell trans-
plantation (HSCT). T-cell depletion was carried out by the use of
high-dose Alemtuzumab (100 mg or 60 mg for unrelated or sibling
donor transplantation, respectively). Here, we provide clinical fol-
low-up data of 101 patients with different hematologic diseases
and a median observation time of 1.5 years (range, 6-84 months).
Median age was 56 years (range, 20-71). Stem cell source were pe-
ripheral blood stem cells of matched siblings (n 5 15), matched un-
related (n 5 48), or unrelated donors with single HLA mismatches
(n5 38). Tapering of Cyclosporin A was started in the 6th week after
transplantation. Subsequently, CD8depl DLI were administered pro-
phylactically in escalating doses starting with 1x106 CD4 T cells/kg
bodyweight. 39 patients received at least one dose of DLI. Among
patients who did not qualify for DLI, 46 patients had primary
GVHD. In 16 patients DLI were not administered for other reasons.
Following DLI, acute GVHDwas the major reason for withholding
subsequent DLI-doses (64%) and 30% suffered from acute GVHD
\ 2. Extensive chronic GVHD was diagnosed in 10% of the pa-
tients. The 1 and 3 year overall survival was 63% and 43%, respec-
tively. Survival significantly differed between the DLI and non
DLI group after 3 years (62% vs. 27%, p 5 0.002). When the DLI
group was compard to those patients who did not receive DLI for
other reasons than primary GVHD, the difference in overall survival
was similar (62% vs. 28%, p5 0.01). The presence of GVHD at any
time was associated with a reduced relapse rate (56% vs. 31%, p 5
0.013), independent of DLI.We demonstrated that 21 of 24 patients
(84%)with decreasingT-cell chimerism (TCC) converted to full do-
nor following CD8depl DLI. In contrast, only 2 of 8 patients (25%)
with decreasing TCC in the non-DLI group converted spontane-
ously.
In summary, we observed that the application of prophylactic
CD8depl DLI was associated with a survival benefit – even though
the nature of the trial does not argue for a causal relationship. Our
data strongly ask for randomized trials either comparing prophylac-
tic application of CD8depl DLI vs. no DLI or CD8depl vs. non-ma-
nipulated DLI in a preemptive setting.35
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Background: The most important mechanism for natural protec-
tion against HIV transmission is a mutation in the CCR5 gene lead-
ing to a 32-base-pair deletion (CCR5-delta32) and a non-functional
CCR5 protein. Prior to 2001, Chow et al pioneered the concept to
screen allogeneic stem cell donors for those homozygous for
CCR5-delta32 to transplant HIV infected patients (U.S. patent
2003/0099621 A1), as acknowledged by Hutter et al recently (The-
ScientificWorld Journal, 2011;11:1068-1076). Hutter et al (NEJM
2009;360:692-698) performed a bone marrow transplant in a patient
with acute leukemia who was infected with HIV using a donor ho-
mozygous for the CCR5-delta32 deletion. More than 4 years later
the patient does not require antiretrovial therapy and no viral load
or proviral DNA can be detected. However, this procedure cannot
be generalized using adult donors because the variant allele is quite
unusual (\1% of Caucasians, and much lower in other ethnic
groups) and a very close HLA match is required between adult do-
nors and patients.
Hypothesis: Cord blood HCT requires HLA matching of only 4 of
6 alleles. Therefore, our hypothesis is that an inventory of cord blood
